Richard Law CFA
Stock Analyst at Goldman Sachs
(3.27)
# 2,449
Out of 5,032 analysts
132
Total ratings
42.9%
Success rate
5.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Reiterated: Hold | $28 | $31.01 | -9.69% | 9 | Oct 5, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Hold | $33 → $38 | $28.38 | +33.90% | 3 | Sep 22, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $20 → $18 | $7.92 | +127.27% | 11 | Sep 14, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $186 | $138.69 | +34.11% | 8 | Aug 31, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $39 → $40 | $18.22 | +119.54% | 11 | Aug 19, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $42 → $40 | $21.95 | +82.23% | 13 | Aug 12, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $18 → $20 | $16.56 | +20.77% | 5 | Aug 11, 2026 | |
| RCUS Arcus Biosciences | Rated: Buy | $34 → $42 | $24.28 | +72.98% | 4 | Aug 10, 2026 | |
| SLN Silence Therapeutics | Reiterated: Sell | $4 | $9.83 | -59.31% | 4 | Jul 27, 2026 | |
| COAG Hemab Therapeutics Holdings | Reiterated: Buy | $36 → $46 | $28.37 | +62.14% | 2 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $11 → $12 | $10.95 | +9.59% | 8 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $3 | $2.48 | +20.97% | 7 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $29 → $33 | $23.92 | +37.96% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $36 → $31 | $8.11 | n/a | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $47 | $25.23 | n/a | 4 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $62 → $63 | $54.00 | n/a | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $36 → $37 | $105.98 | n/a | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 | $12.37 | n/a | 7 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $9.87 | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $7.31 | n/a | 5 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 → $14 | $2.73 | n/a | 3 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $10 | $2.88 | n/a | 2 | Feb 24, 2023 |
Celldex Therapeutics
Oct 5, 2026
Reiterated: Hold
Price Target: $28
Current: $31.01
Upside: -9.69%
Viking Therapeutics
Sep 22, 2026
Reiterated: Hold
Price Target: $33 → $38
Current: $28.38
Upside: +33.90%
Olema Pharmaceuticals
Sep 14, 2026
Reiterated: Buy
Price Target: $20 → $18
Current: $7.92
Upside: +127.27%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $186
Current: $138.69
Upside: +34.11%
Viridian Therapeutics
Aug 19, 2026
Reiterated: Buy
Price Target: $39 → $40
Current: $18.22
Upside: +119.54%
Mineralys Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $42 → $40
Current: $21.95
Upside: +82.23%
Bicara Therapeutics
Aug 11, 2026
Rated: Hold
Price Target: $18 → $20
Current: $16.56
Upside: +20.77%
Arcus Biosciences
Aug 10, 2026
Rated: Buy
Price Target: $34 → $42
Current: $24.28
Upside: +72.98%
Silence Therapeutics
Jul 27, 2026
Reiterated: Sell
Price Target: $4
Current: $9.83
Upside: -59.31%
Hemab Therapeutics Holdings
Jul 13, 2026
Reiterated: Buy
Price Target: $36 → $46
Current: $28.37
Upside: +62.14%
May 11, 2026
Reiterated: Sell
Price Target: $11 → $12
Current: $10.95
Upside: +9.59%
Mar 27, 2026
Reiterated: Sell
Price Target: $3
Current: $2.48
Upside: +20.97%
Feb 27, 2026
Reiterated: Hold
Price Target: $29 → $33
Current: $23.92
Upside: +37.96%
Aug 15, 2023
Reiterated: Hold
Price Target: $36 → $31
Current: $8.11
Upside: n/a
Aug 9, 2023
Reiterated: Hold
Price Target: $47
Current: $25.23
Upside: n/a
Aug 8, 2023
Reiterated: Hold
Price Target: $62 → $63
Current: $54.00
Upside: n/a
Aug 4, 2023
Reiterated: Hold
Price Target: $36 → $37
Current: $105.98
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $76
Current: $12.37
Upside: n/a
May 12, 2023
Reiterated: Hold
Price Target: $11
Current: $9.87
Upside: n/a
May 5, 2023
Reiterated: Buy
Price Target: $61
Current: $7.31
Upside: n/a
May 5, 2023
Reiterated: Hold
Price Target: $15 → $14
Current: $2.73
Upside: n/a
Feb 24, 2023
Upgraded: Hold
Price Target: $10
Current: $2.88
Upside: n/a